Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir, Daclatasvir, and Sofosbuvir in Decompensated HCV
NCT02262728Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of simeprevir in chronic hepatitis C (CHC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Virologic Response 12 Weeks After End of Treatment at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
simeprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02262728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262728.